Microbial regulation of GLP-1 and L-cell biology

Molecular Metabolism

Volumn 5, Issue 9, 2016, Pages 753-758

  Greiner, Thomas U ^a   Bäckhed, Fredrik ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b University of Copenhagen   (Denmark)

Author keywords

Enteroendocrine; Gut; L cells; Metabolites; Microbiota

Indexed keywords

BILE ACID; CHOLECYSTOKININ; GLUCAGON LIKE PEPTIDE 1; INCRETIN; PEPTIDE YY; SHORT CHAIN FATTY ACID;

CELL INTERACTION; CELL POPULATION; CELL REGENERATION; DIETARY FIBER; ENTEROENDOCRINE CELL; GASTROINTESTINAL TRANSIT; GLUCOSE TOLERANCE; HORMONE RELEASE; HUMAN; ILEUM; INSULIN RELEASE; INTESTINE FLORA; L CELL LINE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SMALL INTESTINE;

EID: 84971596983     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.05.012     Document Type: Review

References (71)

1. [1] Savage, D.C., Microbial ecology of the gastrointestinal tract. The Annual Review of Microbiology 31 (1977), 107–133.
2. [2] Berg, R.D., The indigenous gastrointestinal microflora. Trends in Microbiology 4:11 (1996), 430–435.
3. [3] Sender, R., Fuchs, S., Milo, R., Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164:3 (2016), 337–340.
4. [4] Li, J., Jia, H., Cai, X., Zhong, H., Feng, Q., Sunagawa, S., et al. An integrated catalog of reference genes in the human gut microbiome. Nature Biotechnology 32:8 (2014), 834–841.
5. [5] Tremaroli, V., Backhed, F., Functional interactions between the gut microbiota and host metabolism. Nature 489:7415 (2012), 242–249.
6. [6] Badman, M.K., Flier, J.S., The gut and energy balance: visceral allies in the obesity wars. Science 307:5717 (2005), 1909–1914.
7. [7] Hocker, M., Wiedenmann, B., Molecular mechanisms of enteroendocrine differentiation. Annals of the New York Academy of Sciences 859 (1998), 160–174.
8. [8] Rehfeld, J.F., The new biology of gastrointestinal hormones. Physiological Reviews 78:4 (1998), 1087–1108.
9. [9] Gribble, F.M., Reimann, F., Enteroendocrine cells: chemosensors in the intestinal epithelium. The Annual Review of Physiology 78 (2016), 277–299.
10. [10] Meek, C.L., Lewis, H.B., Reimann, F., Gribble, F.M., Park, A.J., The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 77 (2016), 28–37.
11. [11] Holst, J.J., The physiology of glucagon-like peptide 1. Physiological Reviews 87:4 (2007), 1409–1439.
12. [12] Drucker, D.J., Erlich, P., Asa, S.L., Brubaker, P.L., Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proceedings of the National Academy of Sciences of the United States of America 93:15 (1996), 7911–7916.
13. [13] Cani, P.D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:8 (2009), 1091–1103.
14. [14] Simonsen, L., Pilgaard, S., Orskov, C., Rosenkilde, M.M., Hartmann, B., Holst, J.J., et al. Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. American Journal of Physiology, Gastrointestinal and Liver Physiology 293:1 (2007), G288–G295.
15. [15] Koehler, J.A., Baggio, L.L., Yusta, B., Longuet, C., Rowland, K.J., Cao, X., et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metabolism 21:3 (2015), 379–391.
16. [16] Dakin, C.L., Gunn, I., Small, C.J., Edwards, C.M., Hay, D.L., Smith, D.M., et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:10 (2001), 4244–4250.
17. [17] Wynne, K., Park, A.J., Small, C.J., Patterson, M., Ellis, S.M., Murphy, K.G., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54:8 (2005), 2390–2395.
18. [18] Wynne, K., Park, A.J., Small, C.J., Meeran, K., Ghatei, M.A., Frost, G.S., et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. International Journal of Obesity (London) 30:12 (2006), 1729–1736.
19. [19] Pocai, A., Carrington, P.E., Adams, J.R., Wright, M., Eiermann, G., Zhu, L., et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58:10 (2009), 2258–2266.
20. [20] Grosse, J., Heffron, H., Burling, K., Akhter Hossain, M., Habib, A.M., Rogers, G.J., et al. Insulin-like peptide 5 is an orexigenic gastrointestinal hormone. Proceedings of the National Academy of Sciences of the United States of America 111:30 (2014), 11133–11138.
21. [21] Lee, Y.S., De Vadder, F., Tremaroli, V., Wichmann, A., Mithieux, G., Backhed, F., Insulin-like peptide 5 is a microbially regulated peptide that promotes hepatic glucose production. Molecular Metabolism 5:4 (2016), 263–270.
22. [22] Donohoe, D.R., Wali, A., Brylawski, B.P., Bultman, S.J., Microbial regulation of glucose metabolism and cell-cycle progression in mammalian colonocytes. PLoS One, 7(9), 2012, e46589.
23. [23] McMahon, L.R., Wellman, P.J., PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. American Journal of Physiology 274:1 Pt 2 (1998), R23–R29.
24. [24] Batterham, R.L., Cowley, M.A., Small, C.J., Herzog, H., Cohen, M.A., Dakin, C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:6898 (2002), 650–654.
25. [25] Todd, J.F., Edwards, C.M., Ghatei, M.A., Mather, H.M., Bloom, S.R., Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clinical Science (London) 95:3 (1998), 325–329.
26. [26] Batterham, R.L., Bloom, S.R., The gut hormone peptide YY regulates appetite. Annals of the New York Academy of Sciences 994 (2003), 162–168.
27. [27] Savage, A.P., Adrian, T.E., Carolan, G., Chatterjee, V.K., Bloom, S.R., Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 28:2 (1987), 166–170.
28. [28] Pironi, L., Stanghellini, V., Miglioli, M., Corinaldesi, R., De Giorgio, R., Ruggeri, E., et al. Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology 105:3 (1993), 733–739.
29. [29] Layer, P., Holst, J.J., Grandt, D., Goebell, H., Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Digestive Diseases and Sciences 40:5 (1995), 1074–1082.
30. [30] Nauck, M.A., Niedereichholz, U., Ettler, R., Holst, J.J., Orskov, C., Ritzel, R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology 273:5 Pt 1 (1997), E981–E988.
31. [31] Wichmann, A., Allahyar, A., Greiner, T.U., Plovier, H., Lunden, G.O., Larsson, T., et al. Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host & Microbe 14:5 (2013), 582–590.
32. [32] Engelstoft, M.S., Egerod, K.L., Holst, B., Schwartz, T.W., A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metabolism 8:6 (2008), 447–449.
33. [33] Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature Medicine 11:1 (2005), 90–94.
34. [34] Edfalk, S., Steneberg, P., Edlund, H., Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57:9 (2008), 2280–2287.
35. [35] Lauffer, L.M., Iakoubov, R., Brubaker, P.L., GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58:5 (2009), 1058–1066.
36. [36] Reimann, F., Habib, A.M., Tolhurst, G., Parker, H.E., Rogers, G.J., Gribble, F.M., Glucose sensing in L cells: a primary cell study. Cell Metabolism 8:6 (2008), 532–539.
37. [37] Moriya, R., Shirakura, T., Ito, J., Mashiko, S., Seo, T., Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. American Journal of Physiology, Endocrinology and Metabolism 297:6 (2009), E1358–E1365.
38. [38] Cummings, J.H., Pomare, E.W., Branch, W.J., Naylor, C.P., Macfarlane, G.T., Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28:10 (1987), 1221–1227.
39. [39] Koh, A., De Vadder, F., Kovatcheva-Datchary, P., Bäckhed, F., From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell, 2016 Accepted in principle.
40. [40] Tolhurst, G., Heffron, H., Lam, Y.S., Parker, H.E., Habib, A.M., Diakogiannaki, E., et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:2 (2012), 364–371.
41. [41] Karaki, S., Tazoe, H., Hayashi, H., Kashiwabara, H., Tooyama, K., Suzuki, Y., et al. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. The Journal of Molecular Histology 39:2 (2008), 135–142.
42. [42] Tazoe, H., Otomo, Y., Kaji, I., Tanaka, R., Karaki, S.I., Kuwahara, A., Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. Journal of Physiology and Pharmacology 59:Suppl. 2 (2008), 251–262.
43. [43] Nohr, M.K., Pedersen, M.H., Gille, A., Egerod, K.L., Engelstoft, M.S., Husted, A.S., et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology 154:10 (2013), 3552–3564.
44. [44] Lin, H.V., Frassetto, A., Kowalik, E.J. Jr., Nawrocki, A.R., Lu, M.M., Kosinski, J.R., et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One, 7(4), 2012, e35240.
45. [45] Bjursell, M., Admyre, T., Goransson, M., Marley, A.E., Smith, D.M., Oscarsson, J., et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. American Journal of Physiology, Endocrinology and Metabolism 300:1 (2011), E211–E220.
46. [46] Ussar, S., Griffin, N.W., Bezy, O., Fujisaka, S., Vienberg, S., Softic, S., et al. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. Cell Metabolism 22:3 (2015), 516–530.
47. [47] Midtvedt, T., Microbial bile acid transformation. American Journal of Clinical Nutrition 27:11 (1974), 1341–1347.
48. [48] Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. Journal of Lipid Research 47:2 (2006), 241–259.
49. [49] Katsuma, S., Hirasawa, A., Tsujimoto, G., Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochemical and Biophysical Research Communications 329:1 (2005), 386–390.
50. [50] Brighton, C.A., Rievaj, J., Kuhre, R.E., Glass, L.L., Schoonjans, K., Holst, J.J., et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. Endocrinology 156:11 (2015), 3961–3970.
51. [51] Trabelsi, M.S., Daoudi, M., Prawitt, J., Ducastel, S., Touche, V., Sayin, S.I., et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nature Communication, 6, 2015, 7629.
52. [52] Habib, A.M., Richards, P., Cairns, L.S., Rogers, G.J., Bannon, C.A., Parker, H.E., et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153:7 (2012), 3054–3065.
53. [53] Egerod, K.L., Engelstoft, M.S., Grunddal, K.V., Nohr, M.K., Secher, A., Sakata, I., et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 153:12 (2012), 5782–5795.
54. [54] Zoetendal, E.G., Raes, J., van den Bogert, B., Arumugam, M., Booijink, C.C., Troost, F.J., et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. ISME Journal 6:7 (2012), 1415–1426.
55. [55] Johansson, M.E., Phillipson, M., Petersson, J., Velcich, A., Holm, L., Hansson, G.C., The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proceedings of the National Academy of Sciences of the United States of America 105:39 (2008), 15064–15069.
56. [56] Sayin, S.I., Wahlstrom, A., Felin, J., Jantti, S., Marschall, H.U., Bamberg, K., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metabolism 17:2 (2013), 225–235.
57. [57] Le Poul, E., Loison, C., Struyf, S., Springael, J.Y., Lannoy, V., Decobecq, M.E., et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. The Journal of Biological Chemistry 278:28 (2003), 25481–25489.
58. [58] Yusta, B., Baggio, L.L., Koehler, J., Holland, D., Cao, X., Pinnell, L.J., et al. GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R. Diabetes 64:7 (2015), 2537–2549.
59. [59] Kamal, N., Chami, T., Andersen, A., Rosell, F.A., Schuster, M.M., Whitehead, W.E., Delayed gastrointestinal transit times in anorexia nervosa and bulimia nervosa. Gastroenterology 101:5 (1991), 1320–1324.
60. [60] Germain, N., Galusca, B., Le Roux, C.W., Bossu, C., Ghatei, M.A., Lang, F., et al. Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin. American Journal of Clinical Nutrition 85:4 (2007), 967–971.
61. [61] Ruttimann, E.B., Arnold, M., Hillebrand, J.J., Geary, N., Langhans, W., Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150:3 (2009), 1174–1181.
62. [62] Deacon, C.F., Johnsen, A.H., Holst, J.J., Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. Journal of Clinical Endocrinology & Metabolism 80:3 (1995), 952–957.
63. [63] Vilsboll, T., Krarup, T., Sonne, J., Madsbad, S., Volund, A., Juul, A.G., et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism 88:6 (2003), 2706–2713.
64. [64] Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132:6 (2007), 2131–2157.
65. [65] D'Alessio, D.A., What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract. Endocrinology 152:8 (2011), 2925–2926.
66. [66] Smith, E.P., An, Z., Wagner, C., Lewis, A.G., Cohen, E.B., Li, B., et al. The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metabolism 19:6 (2014), 1050–1057.
67. [67] Richards, P., Parker, H.E., Adriaenssens, A.E., Hodgson, J.M., Cork, S.C., Trapp, S., et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63:4 (2014), 1224–1233.
68. [68] Vahl, T.P., Tauchi, M., Durler, T.S., Elfers, E.E., Fernandes, T.M., Bitner, R.D., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:10 (2007), 4965–4973.
69. [69] Sisley, S., Gutierrez-Aguilar, R., Scott, M., D'Alessio, D.A., Sandoval, D.A., Seeley, R.J., Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. Journal of Clinical Investigation 124:6 (2014), 2456–2463.
70. [70] Lamont, B.J., Li, Y., Kwan, E., Brown, T.J., Gaisano, H., Drucker, D.J., Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. Journal of Clinical Investigation 122:1 (2012), 388–402.
71. [71] Eissele, R., Goke, R., Willemer, S., Harthus, H.P., Vermeer, H., Arnold, R., et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. European Journal of Clinical Investigation 22:4 (1992), 283–291.